DarrenKeithMcGuireMD

PubMed

• Metabolic Effects of the SGLT2 Inhibitor Dapagliflozin in Heart Failure Across the Spectrum of Ejection Fraction.
  Senthil Selvaraj, Shachi Patel, Andrew J Sauer, Robert W McGarrah, Philip Jones
  Circulation. Heart Failure. 2024-11-01
• Is This the Real Life? Real-World Evidence of Empagliflozin in Health Care Resource Utilization and Cost.
  Josephine Harrington, Yu Mi Kang, Darren K McGuire
  Diabetes Care. 2024-11-01
• Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide 1 Receptor Agonists: A One-Two Punch?
  Josephine Harrington, Darren K McGuire, Silvio E Inzucchi
  JACC. Heart Failure. 2024-11-01

Journal Articles

• Trends in Hospitalizations for Heart Failure and Ischemic Heart Disease Among US Adults with Diabetes  
  Michael C Honigberg, Ravi B Patel, Javed Butler, Darren K Mcguire, JAMA Cardiology
• Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure  
  Deepak L Bhatt, Darren K Mcguire, Jeffrey M Testani, Pablo Lapuerta, Bertram Pitt, The New England Journal of Medicine
• Association of SGLT2 Inhibitors with Cardiovascular and Kidney Outcomes in Patients with Type 2 Diabetes  
  Darren K Mcguire, Samuel Dagogo-Jack, Urszula Masiukiewicz, JAMA Cardiology
• Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes  
  Samuel Dagogo-Jack, Urszula Masiukiewicz, Robert Frederich, Darren K Mcguire, The New England Journal of Medicine
• Use of Glucagon-like Peptide-1 Receptor Agonists in Patients with Type 2 Diabetes and Cardiovascular Disease  
  Michael C Honigberg, Darren K Mcguire, Muthiah Vaduganathan, JAMA Cardiology
• Improved Time in Range and Glycemic Variability with Sotagliflozin in Combination with Insulin in Adults with Type 1 Diabetes: A Pooled Analysis of 24-Week Continuous ...  
  Jake A Kushner, John B Buse, Satish K Garg, Darren K McGuire, Diabetes Care
• Lower Rates of Cardiovascular Events and Mortality Associated with Liraglutide Use in Patients Treated with Basal Insulin – A DEVOTE Subanalysis (DEVOTE 10)  
  John B Buse, Darren K McGuire, Richard E Pratley, Diabetes, Obesity and Metabolism
• Fasiglifam-Induced Liver Injury in Patients with Type 2 Diabetes: Results of a Randomized Controlled Cardiovascular Outcomes Safety Trial  
  Darren McGuire, MD, Diabetes Care
• Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes  
  Stephen D Wiviott, Marc S Sabatine, Christian T Ruff, Marc P Bonaca, Deepak L Bhatt, Darren K McGuire, The New England Journal of Medicine
• Heart Failure Epidemiology in Patients with Diabetes Mellitus Without Coronary Heart Disease  
  James L Januzzi, Darren K Mcguire, Javed Butler, Journal of Cardiac Failure
• Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults with Type 2 Diabetes and High Cardiovascular and Renal Risk  
  Steven E Kahn, John H Alexander, Robert D Toto, Darren K McGuire, JAMA
• Relation of Plasma Ceramides to Visceral Adiposity, Insulin Resistance and the Development of Type 2 Diabetes Mellitus: The Dallas Heart Study  
  Ian J Neeland, Darren K McGuire, Shruti Singh, Diabetologia
• Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients  
  Erin A Bohula, Stephen D Wiviott, Benjamin M Scirica, Darren K McGuire, Marc S Sabatine, Marc P Bonaca, Christian T Ruff, Silvio E Inzucchi, The New England Journal of Medicine
• Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients  
  Christina L. Fanola, Darren K. McGuire, Silvio E. Inzucchi, Erin A. Bohula, The New England Journal of Medicine
• Management of Patients with Diabetes and Heart Failure with Reduced Ejection Fraction: An International Comparison  
  James L Januzzi, Mikhail Kosiborod, Frederick A Masoudi, Darren K McGuire, Suzanne V Arnold, Gregg C Fonarow, Diabetes, Obesity and Metabolism
• Sotagliflozin in Combination with Optimized Insulin Therapy in Adults with Type 1 Diabetes: The North American inTandem1 Study  
  Satish K Garg, John B Buse, Jake A Kushner, Darren K McGuire, Diabetes Care
• And Hypoglycemia Reductions at 24 and 52 Weeks with Sotagliflozin in Combination with Insulin in Adults with Type 1 Diabetes: The European inTandem2 Study  
  Jake A Kushner, Darren K McGuire, Diabetes Care
• Long-Term Association of LDL Cholesterol with Cardiovascular Mortality in Individuals at Low 10-Year Risk of Atherosclerotic Cardiovascular Disease: Results from the C...  
  Abdullah SM, Defina LF, Leonard D, Barlow C, Radford NB, Willis BL, Rohatgi A, McGuire DK, de Lemos JA, Grundy SM, Berry JD, Khera A, Circulation, 1/1/2018
• Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes  
  Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, Zelniker T, Kuder J, Murphy SA, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Ruff CT, Gause-N..., N Engl J Med, 1/1/2018
• SGLT2 Inhibitors for Primary and Secondary Prevention of Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Meta-Analysis of Cardiovascular Outcomes Trials  
  Zelniker TA, Wiviott SD, Raz I, Im K, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Furtado RHM, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS, Lancet, 1/1/2018
• Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk the CARMELINA Randomized Clinical...  
  Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N, Alexander JH, Pencina M, Toto R, Wanner C, Zinman B, Woerle HJ, Baanstra D, Pfarr E, Sven Schnaidt, ..., JAMA, 1/1/2018
• Heart Failure Epidemiology in Patients with Diabetes Mellitus without Coronary Heart Disease: Insights from the Health, Aging, and Body Composition Study  
  Khan H, Anker SD, Januzzi Jr JL, McGuire DK, Sattar N, Woerle HJ, Butler J, J Cardiac Failure, 1/1/2018
• Relation of Plasma Ceramides to Visceral Adiposity, Insulin Resistance, and the Development of Type 2 Diabetes Mellitus: The Dallas Heart Study  
  Neeland IJ, Singh S, McGuire DK, Vega GL, Roddy T, Reilly DF, Castro-Perez J, Kozlitina J, Scherer PE, Diabetologia, 1/1/2018
• Linagliptin Effects on Heart Failure Outcomes in Participants with Type 2 Diabetes at High CV and Renal Risk in CARMELINA( R)  
  McGuire DK, Alexander JH, Johansen OE, Perkovic V, Rosenstock J , Cooper ME, Wanner C, Kahn SE, Toto R, Zinman B, Baanstra D, Pfarr E, Schnaidt S, Meinicke T, George J..., Circulation, 1/1/2018
• Design and Baseline Characteristics of the eValuation of ERTugliflozin effIcacy and Safety Cardiovascular Outcomes Trial (VERTIS-CV)  
  Cannon CP, McGuire DK, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S,Charbonnel B, Shih WJ,Gallo S, Masiukiewicz U, Golm G, Cosentino F, Lauring B, Terra SG, on behalf ..., Am Heart J, 1/1/2018
• Join now to see all

Books/Book Chapters

• Braunwald's Heart Disease: A textbook of cardiovascular medicine 
  Chapter: Diabetes and the cardiovascular system 
  McGuire DKEditors: Mann DL, Zipes DP, Libby P, Bonow RO.Saunders Elsevier, Philadelphia, PAEdition 10th,2015
• Prevention of Cardiovascular Disease: A Companion to Braunwald's Heart Disease 
  Chapter: Diabetes and Cardiovascular Disease 
  Gore MO, Inzucchi S, McGuire DKEditors: Blumenthal RS, Foody JM, and Wong ND.Saunders, an imprint of Elsvier, Inc., Philadelphia, PAEdition 1st,2011
• Evidence-based Management of Diabetes. 
  Chapter: Hyperglycemia in acute coronary syndromes. 
  Gore MO, Kosiborod M, McGuire DKEditors: Vora J, Buse J.tfm publishing Ltd, Shrewsbury, United Kingdom2011
• Braunwald�s Heart Disease: A textbook of cardiovascular medicine 
  Chapter: Diabetes and the cardiovascular system 
  McGuire DKEditors: Libby P, Bonow RO, Mann DL, Zipes DP.Saunders Elsevier, Philadelphia, PAEdition 9th,2010
• Current Controversies and Changing Practice 
  Chapter: The Cardiovascular Quandary, in Hypoglycemia in Type 2 Diabetes 
  McGuire DKEditors: Henry RR.Royal Society of Medicine Press Limited, London, United Kingdom2010
• Clinical Research: From Proposal to Implementation 
  Chapter: Writing Informed Consent Documents and Obtaining Informed Consent 
  Clark A, Rivera SM, Sheppard D, McGuire DK, McPhaul MJEditors: Michael J. McPhaul and Robert D. Toto.Lippincott Williams & Wilkins, Philadelphia, PAEdition 1st,2010
• Harrison�s Online Textbook of Internal Medicine 
  Chapter: Cardiovascular Considerations for the Use of Thiazolidinedione Medications 
  McGuire DK, Inzucchi SEEditors: Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL, Jameson L, and Loscalzo J.Edition 17th,2009
• Contemporary Endocrinology: Type 2 Diabetes Mellitus: An Evidence-based Approach to Practical Management 
  Chapter: Management of Coronary Artery Disease in Type 2 Diabetes Mellitus 
  Petersen JL, McGuire DKEditors: Feinglos MN and Bethel MA.Humana Press, Totowa, NJ2008
• ACC SAP Version 6 
  Chapter: Risk factors-Diabetes and CHD. 
  McGuire DK, Rutherford JDEditors: Richard P. Lewis.2005
• The Handbook of Diabetes and Cardiovascular Disease. 
  Chapter: Epidemiology of Diabetes and Cardiovascular Disease 
  McGuire DK, Rao SVEditors: Steven P. Marso.Remedica Publishing, London, United Kingdom2003
• The Elderly, Woman, and Patient with Diabetes in Acute Coronary Syndromes: A Companion to Braunwald's Heart Disease. 
  McGuire DK, Newby LK, Biswas M, Hochman JSEditors: Pierre Theroux.Harcourt Health Sciences2003
• New Standards of AMI Care. Part V: Reperfusion of Special Populations. 
  Chapter: Caring for the patient with diabetes and myocardial infarction. 
  Page 13 - 25Califf RM, McGuire DK, Feinglos MAEditors: Califf, RM.Exerpta Medica, Inc, New York, NY1998
• Join now to see all

Abstracts/Posters

• A1C : Glucose management in type 2 diabetes mellitus.
  Goyal A, Kosiborod M, McGuire DK, Garber AJ, American College of Cardiology Foundation Diabetes Self-Assessment Program, Washington, DC, 1/1/2011

Lectures

• Assessment of Omega‐3 Carboxylic Acids in Statin Treated Patients with High Levels of Triglycerides and Low Levels of High Density Lipoprotein Cholesterol: Rationale a... 
  Scientific Sessions 2008, New Orleans, Louisiana, USA
• Assessment of Omega‐3 Carboxylic Acids in Statin Treated Patients with High Levels of Triglycerides and Low Levels of High Density Lipoprotein Cholesterol: Rationale a... 
  Scientific Sessions 2007, Orlando, Florida, USA
• Assessment of Omega‐3 Carboxylic Acids in Statin Treated Patients with High Levels of Triglycerides and Low Levels of High Density Lipoprotein Cholesterol: Rationale a... 
  International Chair on Cardiometabolic Risk, 2nd International Congress on Abdominal Obesity, Buenos
• Assessment of Omega‐3 Carboxylic Acids in Statin Treated Patients with High Levels of Triglycerides and Low Levels of High Density Lipoprotein Cholesterol: Rationale a... 
  American Heart Association, Scientific Sessions 2008, New Orleans, Louisiana, USA
• Assessment of Omega‐3 Carboxylic Acids in Statin Treated Patients with High Levels of Triglycerides and Low Levels of High Density Lipoprotein Cholesterol: Rationale a... 
  American College of Cardiology, 59th Annual Scientific Session & Expo, Atlanta, Georgia, USA
• Assessment of Omega‐3 Carboxylic Acids in Statin Treated Patients with High Levels of Triglycerides and Low Levels of High Density Lipoprotein Cholesterol: Rationale a... 
  American Heart Association, Scientific Sessions 2007, Orlando, Florida, USA
• Assessment of Omega‐3 Carboxylic Acids in Statin Treated Patients with High Levels of Triglycerides and Low Levels of High Density Lipoprotein Cholesterol: Rationale a... 
  59th Annual Scientific Session & Expo, Atlanta, Georgia, USA
• Update on Cardiovascular and Kidney Outcomes with SGLT2 Inhibitors. 
  Kolkatta, Cochin, Pune, New Delhi and Meerut, India - 1/29/2019
• Lessons from the CARMELINA Trial 
  UT Southwestern, Dallas, TX - 1/15/2019
• Update on Cardiovascular and Kidney Outcomes with SGLT2 Inhibitors 
  Texas Health Resources Presbyterian Hospital, Dallas, TX - 1/2/2019
• CV Outcomes Trials in Diabetes: Selected Lessons Learned thus Far 
  Multiple Locations, 2017, 2018, 2019 - 1/1/2019
• Assessment of Omega‐3 Carboxylic Acids in Statin Treated Patients with High Levels of Triglycerides and Low Levels of High Density Lipoprotein Cholesterol: Rationale a... 
  2nd International Congress on Abdominal Obesity, Buenos Aires, Argentina
• Evidence-based approaches to reducing premature cardiovascular mortality in patients with type 2 diabetes and established CV disease. 
  Munich, Germany - 1/25/2018
• The Future of Cardiovascular Outcomes Trials in Diabetes-Change course: We Need to Refocus Our Approach and Questions 
  Orlando, FL - 1/22/2018
• Anti-hyperglycemic Agents and Atherosclerotic CV Disease: A Cardiologist�s Perspective 
  Atlanta, GA, 2018; Big Sky, MT, 2018 - 1/21/2018
• Uncertainties in Cardiometabolic Management: Heart Failure and Diabetes 
  Big Sky, MT - 1/21/2018
• Introduction to Biostatistics 
  UT Southwestern, Dallas, TX, 2017, 2018 - 1/16/2018
• New Therapeutics in Diabetes: New Opportunity to Lower CV Risk 
  Dallas, TX - 1/12/2018
• Lessons of a Cardiodiabetologist 
  University of Toronto, Toronto, Ontario, Canada - 1/12/2018
• Heart Failure and Related Outcomes in the CARMELINA Trial 
  Chicago, IL - 1/11/2018
• Lessons Learned Thus Far from Cardiovascular Outcomes Trials in Diabetes: Cardiologist Perspective 
  University of Michigan, Ann Arbor, MI - 1/11/2018
• From Clinical Trials to Clinical Practice: Applying Cardiovascular Outcome Trial Data to T2DM Management 
  Chicago, IL - 1/9/2018
• Update on the SGLT2 inhibitor cardiovascular outcome trials 
  New Orleans, LA - 1/9/2018
• Type 2 Diabetes, CVD and Heart Failure: perspectives by a cardiologist 
  Aachen, Germany - 1/8/2018
• The Cardio-Diabetes Interface- where to next? 
  Brisbane, Australia; Sydney, Australia; Melbourne, Australia - 1/7/2018
• Join now to see all

Other

• The TECOS Trial of Sitagliptin vs. Placebo: Context and Cardiovascular Observations. 
  Gore MO, McGuire DK
  http://www.acc.org/latest-in-cardiology/articles/2015/11/20/14/19/the-tecos-trial-of-sitagliptin-vs-placebo
  1/23/2015
• MY APPROACH to Sulfonylureas in Patients With Coronary Artery Disease. 
  McGuire DK, Gore O, PracticeUpdate
  http://www.practiceupdate.com/ExpertOpinion/1088/1/8
  1/10/2014
• Consultant Live Podcast: DPP 4 Inhibitors 
  McGuire DK
  http://www.consultantlive.com/cardiovascular-diseases/content/article/10162/2129971
  1/27/2013
• Managing Diabetes and CAD Past, Present and Future: The Cardiologist�s Perspective 
  McGuire DK, Medscape Cardiology CME Webcast
  Amsterdam, The Netherlands - 1/2/2013
• Aspirin for Primary Prevention of Cardiovascular Events in People with Diabetes: The more we know, the more we don't know. 
  Gore MO, McGuire DK, American Heart Association Learning Library
  1/27/2010
• Lipid Management in Patients with Diabetes: LDL Lowering, Then What? 
  Khera A, McGuire DK, Cardiosource Web Site, American College of Cardiology Foundation
  1/4/2010
• Glucose Control in Acute Coronary Syndromes: Making a Hasty Retreat. 
  McGuire DK, Cardiosource Web Site, American College of Cardiology Foundation
  http://www.cardiosource.com/expertopinions/hottopics/article.asp?paperID=343
  1/15/2009
• Cardiovascular Effects of Sodium Glucose Co-transporter 2 (SGLT2) inhibitors: The Search for the How and Why. 
  Neeland IJ, De Albuquerque Rocha N, McGuire DK, Cardiosource, American College of Cardiology Foundation
• Join now to see all